Cost-Effectiveness Analysis of Ofatumumab for the Treatment of Relapsing-Remitting Multiple Sclerosis in Canada

Moogeh Baharnoori, Virender Bhan, Fraser Clift, Kimberly Thomas, Soukaïna Mouallif (), Nicholas Adlard, Philip Cooney, François Blanchette, Barkha P. Patel and Daniel Grima
Additional contact information
Moogeh Baharnoori: Queen’s University
Virender Bhan: The University of British Columbia
Fraser Clift: Memorial University of Newfoundland
Kimberly Thomas: EVERSANA
Soukaïna Mouallif: Novartis Canada Inc.
Nicholas Adlard: Novartis Pharma AG
Philip Cooney: Novartis Ireland Limited
François Blanchette: Novartis Canada Inc.
Barkha P. Patel: EVERSANA
Daniel Grima: EVERSANA

PharmacoEconomics - Open, 2022, vol. 6, issue 6, No 8, 859-870

Abstract: Abstract Background Ofatumumab is a high-efficacy disease-modifying therapy (DMT) approved for first-line treatment of relapsing-remitting multiple sclerosis (RRMS) in Canada. Objective The aim of this study was to evaluate the cost effectiveness of ofatumumab from a Canadian healthcare system perspective. Methods A Markov cohort model was run over 65 years using annual cycles, 1.5% annual discount rate, and 100% treatment discontinuation at 10 years. The British Columbia database informed natural history transition probabilities. Treatment efficacy for DMTs were sourced from a network meta-analysis. Clinical trial data were used to estimate probabilities for treatment-related adverse events. Health utilities and costs were obtained from Canadian sources (if available) and the literature. Results Among first-line indicated therapies for RRMS, ofatumumab was dominant (more effective, lower costs) over teriflunomide, interferons, dimethyl fumarate, and ocrelizumab. Compared with glatiramer acetate and best supportive care, ofatumumab resulted in incremental cost-effectiveness ratios (ICERs) of $24,189 Canadian dollars per quality-adjusted life-year (QALY) and $28,014/QALY, respectively. At a willingness-to-pay threshold of $50,000/QALY, ofatumumab had a 64.3% probability of being cost effective. Among second-line therapies (scenario analysis), ofatumumab dominated natalizumab and fingolimod and resulted in an ICER of $50,969 versus cladribine. Conclusions Ofatumumab is cost effective against all comparators and dominant against all currently approved and reimbursed first-line DMTs for RRMS, except glatiramer acetate.

Date: 2022
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s41669-022-00363-1 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:pharmo:v:6:y:2022:i:6:d:10.1007_s41669-022-00363-1

Ordering information: This journal article can be ordered from
http://www.springer.com/adis/journal/41669

DOI: 10.1007/s41669-022-00363-1

Access Statistics for this article

PharmacoEconomics - Open is currently edited by Timothy Wrightson and Christopher Carswell

More articles in PharmacoEconomics - Open from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().